Articles On Acrux (ASX:ACR)

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Queen Elizabeth II soared off into the heavens Classic Minerals pulls off an amazing impersonation of Her Maj MinRes does absolutely nothing, but banks $1.5bn in value anyway   What a cracker of a day. This morning was an absolute rager,...

Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Pharmaceutical company Acrux (ACR) enters an exclusive commercial agreement with US-based Padagis for one of its products Under the agreement, Padagis will commercialise Acrux’s product and will be responsible for sales, distribution and c...

Antisense announces positive study of ATL1102 Acrux to launch a new product in the US MedAdvisor gets new CEO  Antisense Therapeutics (ASX:ANP) announced a successful study into a new muscle disease indication for its lead drug, ATL1102....

Highlights Firebrick secures patent in Malaysia for Nasodine® Nasal Spray as a treatment and preventative for common cold Nasodine is now protected in 26 countries, with China, Singapore, Japan, and Canada on the pending list Nasodine...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

When it comes to analysing company results, interpretations can differ as widely as Russian news agent Pravda’s reporting of the Ukraine conflict relative to the Kyiv Independent’s. Take the reformed generic drug house Mayne Pharma (ASX:MYX...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

The Australian bourse recouped most of yesterday’s losses despite tech stocks dropping again, this time by 3.49%. The ASX 200 rose 0.78%, closing at 7,411 points, with the gains driven by the resources and energy sectors, which gained 2.3%...

The ASX retreated again as angst over inflation and the withdrawal of stimulus continued to weigh on global markets. The ASX 200 closed at 7,300 – 0.28% lower than Friday’s close. Tech was the biggest laggard, losing nearly 3% but energy an...

ShareCafeAustralia… One Hour In… ASX200 down 62 ASX200 down 62 points (0.9%) to 7257.   Acrux (-3.8%); its license agreement with Harris Pharmaceutical has been terminated due to Harris filing for Chapter 11. Ampol (+3.5%) / Z Energy (+6%)...

Highlights Qantas Airways shares dropped after the ACCC rejected its alliance with Japan Airlines. Omni Bridgeway extended fall after an unfavourable ruling in Wivenhoe floods case. Chorus shares fell after the stock turned ex-dividen...

Highlights Australian benchmark index, the ASX 200, traded higher by 0.3% by mid session. Five of the 11 sectors traded in green, while the energy and material sector gained the most. Sydney Airport topped the gainers’ list on the tak...

Wall Street falls again for fourth consecutive day All three major US stock market benchmarks fell on Friday for the fourth consecutive day. Equity investors are concerned about the rising Delta variant cases, and the impending Fed tapering...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

The ASX 200 health stocks index (XHJ) fell by 1.55% this morning, compared to the broader index which dropped by 0.67%. Topical and and dermatological specialist, Acrux (ASX:ACR), announced that its generic Testosterone Topical Solution USP...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Summary Openpay (ASX:OPY) delivers strong growth in Q4 FY21, marks 141% rise in active plans Rio Tinto (ASX:RIO) commits to fund Jadar lithium project Cashrewards’ (ASX:CRW) future Max™ launch begets strong growth in June quarter...

Summary The ASX 200 traded lower by 24 points or 0.32% at 7,408 by the lunch. Six of 11 sectors were in red, while tech and energy dropped the most. Investment fund Spark Infrastructure Group was the top performer with 5% gain. ...

ASX 200 health stocks index rose by 0.21% this morning, compared to the broader index which fell by 0.22%. Chimeric Therapeutics (ASX:CHM) rose by 6% after obtaining the exclusive license to a novel CAR-T for solid tumours from the Universi...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Over the past month, a number of US FDA approvals have moved the share prices of global pharma stocks, including those traded here on the ASX. The biggest FDA announcement during the month came out of US-based Biogen, which received a contr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Summary The ASX 200 closed 1.48% higher at 7,342.20, recouping previous session losses. Ten of the 11 sectors ended in green, while the energy sector emerged as the top performer with 2.35% gain. Minding firm Pilbara Minerals was the...

Plenty of action on the biotech front today has provided ASX investors with some mouth-watering gains. Suda Pharma (ASX:SUD) led the pack, popping by as much as 44 per cent after announcing an oversubscribed $3.65 million capital raise. The...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Summary The ECT share price has rocketed 50% to AU$0.002, clocking a volume of over 4 million shares. Acrux has received approval from the USFDA for its generic version of Jublia® (efinaconazole) topical solution, 10%. Antilles Gold h...

After a tumultuous journey, biotech Acrux (ASX:ACR) will finally be able to sell its toenail fungus treatment in the USA. The FDA has signed off on Acrux’s generic version of Jublia, a treatment for nail fungus delivered topically (via the...

ShareCafeAustralia…1 hour in… ASX200 up 93 ASX200 up 93 points (1.3%) to 7328.   Acrux (+35%); the US FDA has granted approval of the Co’s generic version of Jublia — an antifungal drug indicated for the topical treatment of infections of...

The Acrux Limited (ASX: ACR) share price has been an exceptionally strong performer on Tuesday. In morning trade, the pharmaceutical company’s shares are up a massive 39% to 16 cents. Why is the Acrux share price rocketing higher? The cata...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Summary The ASX 200 ended 10.70 points or 0.15% higher at 7292.60, setting a new 100-day high. The information technology sector emerged as the top performer for the second straight day with 1.15% gain. Bitcoin, Ether and other crypto...

ShareCafeAustralia…1 hour in… ASX200 up 20 ASX200 up 20 points (0.3%) to 7302.   Acrux (-7%); announced that Almirall has initiated patent litigation against Acrux in the US District Court. Ansell (+0.2%); names Neil Salmon as new CEO.   A...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...